definiens: ( an acronym for ' ~receptor of alpha - fetoprotein " ) shall mean any synthetic or natural molecule, or portion of such molecule, or molecule derivative from another molecule, that in its natural state shows specific binding to any of the following : ( a ) natural or synthetic alpha - fetoprotein ( HAFP " ) ; ( b ) a fragment of AFP ; ( c ) a modification of AFP ; ( d ) a modification of a fragment of AFP ; ( e ) native or synthetic AFP or AFP produced by -4 - genetic engineering, bound or not to fatty acids or other molecules : or ( t ) a fragment of AFP bound to other fatty acids or other molecules ( g ) any derivatives~ parts or polymorphisms ( including without limitation splice variants ) of RECAF, ( h ) any nucleotide sequences with homology to the RECAF gene or RECAFs ' translational sequences~ ( together with any derivatives, parts or splice variants of the corresponding nucleotide sequences ), ( i ) amino acid sequences and proteins encoded by each such nucleotide sequences ( together with any derivatives or parts of such amino acid sequences and proteins ) and U ) glycans and sequences of sugars that specifically bind AFP . ' · Specific binding " as used in this Section, means an interaction between two ( 2 ) molecules that : ( x ) becomes saturated as the concentration of one ( 1 ) of the molecules is increased with respect to the other ; and ( y ) can be competed with the other molecule or an excess of the same molecule unlabeled . In the event ( i ) RECAF is kno\vn as another molecule known in the public domain, and ( ii ) [COMPANY] does not have a product for sale or a technology already licensed to others based on said molecule as of the Effective Date, and ( iii ) [COMPANY] decides to develop and commercialize a product or a technology based on said molecule specifically pertaining to the Field, then such product or technology shall be deemed a Product subject to the terms and conditions of this Agreement